Teva, Glenmark Sign Deferred Prosecutions For Generic Price Fixing, Pay $305M
PHILADELPHIA — A U.S. attorney on Aug. 21 filed two deferred prosecution agreements with drugmakers Teva Pharmaceuticals USA Inc. and Glenmark Pharmaceuticals Inc. USA in which the defendants agree to pay...To view the full article, register now.
Already a subscriber? Click here to view full article